IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Phone650-940-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.60 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) posted its earnings results on Tuesday, August, 6th. The medical equipment provider reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. The medical equipment provider had revenue of $10.43 million for the quarter, compared to the consensus estimate of $10.94 million. IRIDEX had a negative net margin of 26.02% and a negative return on equity of 39.42%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What guidance has IRIDEX issued on next quarter's earnings?
IRIDEX issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $41-44 million, compared to the consensus revenue estimate of $45.02 million.
What price target have analysts set for IRIX?
2 Wall Street analysts have issued 12-month price objectives for IRIDEX's shares. Their predictions range from $7.00 to $7.00. On average, they anticipate IRIDEX's stock price to reach $7.00 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for IRIDEX.
What is the consensus analysts' recommendation for IRIDEX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.
Has IRIDEX been receiving favorable news coverage?
Media headlines about IRIX stock have trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IRIDEX earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for IRIDEX.
Are investors shorting IRIDEX?
IRIDEX saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,270,000 shares, an increase of 161.7% from the August 30th total of 485,300 shares. Based on an average trading volume of 86,400 shares, the short-interest ratio is currently 14.7 days. Approximately 10.7% of the company's stock are short sold. View IRIDEX's Current Options Chain.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include Second Sight Medical Products (EYES), electroCore (ECOR), Soleno Therapeutics (SLNO), Helius Medical Technologies (HSDT), Fc Global Realty (FCRE), Precision Optics (PEYE), Digirad (DRAD), Reshape Lifesciences (RSLS), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), CHF Solutions (CHFS), Nexeon Medsystems (NXNN), Vaso (VASO), Viveve Medical (VIVE) and Escalon Medical (ESMC).
What other stocks do shareholders of IRIDEX own?
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
- Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
- Mr. Romeo R. Dizon, VP of Fin.
- Ms. Leigh Salvo, Head of Investor Relations
- Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $1.89.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $26.00 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.
What is IRIDEX's official website?
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
